POLPHARMA-BIOLOGICS
7.7.2021 11:33:08 CEST | Business Wire | Press release
Polpharma Biologics Group announces that its joint venture company with Santo Holding (Strüngmann Group), Bioeq, has concluded a commercial partnership with Teva Pharmaceutical Industries Ltd. for their biosimilar candidate of the ophthalmological drug Ranibizumab (Lucentis®) in Europe, Canada, Israel and New Zealand.
The reference product is a monoclonal anti-angiogenic antibody fragment (Fab) that has been approved to treat the "wet" type of age-related macular degeneration, a common form of age-related vision loss. Worldwide, at least 25 to 30 million people are affected by age-related macular degeneration. The launch of a biosimilar Ranibizumab can increase market competition, reduce cost and expand patient access with proven analytical and clinical similarity to the original product.
This agreement with Teva complements an existing agreement concluded with Coherus BioSciences, Inc. for commercialisation in the United States.
Dr Joerg Windisch, CEO of the Polpharma Biologics Group, commented on the achievements of the joint venture:
“This is a huge milestone for the progression of a life changing therapeutic. We are proud the development program has been successfully completed, and that, through this agreement, more patients will gain access to highly effective treatments for vision loss including for age-related macular degeneration. This is another demonstration of our passion for providing safe and effective medicines to patients.”
About the Ranibizumab biosimilar
The Ranibizumab biosimilar, FYB201, was originally licensed in from Formycon AG (FRA: FYB/ WKN A1EWVY), a leading German biosimilars company, and subsequently developed by Bioeq AG, a joint venture between Polpharma Biologics and Santo Holding AG (Strüngmann Group). Phase III clinical trials for FYB201 have clinically demonstrated that the efficacy of FYB201 in patients with nAMD is comparable to that of Lucentis®.
Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Biosimilars exhibit proven analytical and clinical similarity to their respective branded reference products.
-------------------------------------------------------------------------------------------------------------------------------------------
About the Polpharma Biologics Group
Polpharma Biologics Group is a biopharmaceutical group focused on the development and manufacture of biosimilars. It provides fully integrated solutions along the biopharmaceutical value chain including cell line development, product and process development and clinical and commercial scale manufacturing to support the development of its proprietary portfolio of products and those of industry partners around the globe.
Polpharma Biologics has two sites in Poland, an advanced research and development center in Gdansk and a commercial scale manufacturing facility in Warsaw. It also has a research center in the Netherlands.
It is the largest Polish biotechnological firm developing and manufacturing biosimilars. It has been active for over 10 years on a scale previously unknown in the Polish biotechnological sector, investing not only in labs and production lines, but also in know-how, creating highly specialised work places and developing co-operation between business and science.
The Group currently employs over 800 people in Poland, including top-class specialists from the country and from around the world.
Learn more at www.polpharmabiologics.com
About Bioeq
Bioeq AG is a Swiss biopharmaceutical joint venture between the Polpharma Biologics Group and the Strüngmann Group. Bioeq develops, licenses and commercializes biosimilars.
Learn more at www.bioeq.ch
About Teva
Teva Pharmaceutical Industries Ltd. has been developing and producing medicines to improve people’s lives for more than a century. Teva is a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with an established presence in generics, they have significant innovative research and operations supporting a growing portfolio of specialty and biopharmaceutical products.
Learn more at www.tevapharm.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210707005415/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Oscilloquartz delivers assured timing for mission-critical harsh environments with ruggedSync™ Series OSA 55101.6.2026 14:00:00 CEST | Press release
News summary: Defense operations require resilient timing architectures that maintain synchronization in contested and GNSS-denied environments ruggedSync™ Series OSA 5510 delivers assured timing and extended holdover in a MIL-qualified platform for tactical, deployable operations Zero-trust resiliency with diversified cPNT sources, including M-Code, PRS and STL, strengthens operational continuity for defense communications, navigation and mission-critical infrastructure Oscilloquartz today launched its ruggedSync™ Series OSA 5510, a ruggedized timing and synchronization platform engineered for defense and other harsh, mission-critical environments. Designed for deployment in tactical communications networks, mobile command centers (MCCs), aviation systems and other highly demanding operational environments, the OSA 5510 combines PTP grandmaster and NTP server functionality with synchronization assurance and resilient holdover in a compact MIL-qualified platform. Multi-band GNSS suppor
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy1.6.2026 14:00:00 CEST | Press release
- FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) submission for povetacicept, an investigational engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in adults with immunoglobulin A nephropathy (IgAN). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026. If approved, povetacicept will become the first commercialized therapy in Vertex’s emerging nephrology franchise. “The Phase 3 RAINIER trial is the largest conducted in IgAN and achieved full enrollment faster than any contemporary IgAN trial, reflecting the significant unmet need in IgAN and our urgency to bring povetacicept to patients with this serious disease,” said Nia Tatsis, Ph.D., Executi
Winston Taylor Completes Historic Transatlantic Combination1.6.2026 13:01:00 CEST | Press release
Transatlantic powerhouse law firm established for the businesses, people, and markets driving capital and innovation Winston Taylor announces today that Winston & Strawn and Taylor Wessing’s U.K.-led business have officially launched as a single combined firm, creating a premier transatlantic law firm built for the needs of the businesses, people, and markets driving capital and innovation. One of the largest transatlantic firms, with more than 1,400 lawyers spanning the United States, the United Kingdom, Europe, Latin America, and the Middle East, Winston Taylor is built to meet clients’ evolving global needs for counsel. “As Winston Taylor, we are centered on a client-first approach and will be working shoulder to shoulder with our clients at the cutting edge of industry and ingenuity,” said Chairman Steve D’Amore. “With that common purpose, we are leveraging both strength and scale by integrating our teams and offices at record speed, working at pace to create a firm that is aligned
Kinaxis Appoints Kristin Russel as Chief Marketing Officer1.6.2026 13:00:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced the appointment of Kristin Russel as Chief Marketing Officer (CMO). Russel will lead Kinaxis’ global marketing organization, overseeing marketing strategy, corporate and market positioning, digital and brand marketing, communications and go-to-market initiatives. Russel will also take the main stage at Kinexions, where she will discuss practical steps organizations can take to move from decisions to outcomes in an increasingly complex operating environment. A tenured marketing executive and recognized industry leader, Russel brings deep experience scaling technology companies and building high impact brands. She joins Kinaxis from symplr, where she served as Chief Marketing Officer and led the development and execution of the company’s comprehensive marketing strategy across branding, digital and product marketing, public relations, community outreach programs, channel partne
Samsung Electronics Begins Shipment of Industry-First HBM4E Samples1.6.2026 12:57:00 CEST | Press release
Samsung's 12-layer HBM4E achieves speeds of up to 16Gbps with improved energy efficiency and thermal performanceProven processes from HBM4 production experience and technology enhancements support increasingly demanding next-generation AI workloads Samsung Electronics, a global leader in advanced memory technology, has begun shipping the industry's first 12-layer HBM4E samples to major global customers, further strengthening its leadership in the next-generation HBM market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601979564/en/ Samsung's 12-layer HBM4E Following the industry’s first mass production and commercial shipment of its industry-leading HBM4 earlier this year, Samsung now extends its HBM roadmap with the introduction of HBM4E samples, addressing the rapidly evolving demands of AI computing and hyperscale infrastructure. "Following the successful mass production of HBM4, Samsung has once again demonstrated i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom